Although limited data exist on the potential clinical benefit of immunotherapy in GBM, the evidence that 12.5% of IDH-wt GBM in adults < 55 years are ultra-mutated may offer alternative therapeutic strategies in this age group. This evidence concerns the gene IDH1 and glioblastoma.